US 8,785,371 B2 · Drug delivery of temozolomide for systemic based treatment of cancer

Abstract

The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.

Claims2

Dependent claims

A pharmaceutical composition, comprising:

a therapeutically effective amount of a polymalic acid-based nanoconjugate of temozolomide (TMZ), wherein the polymalic acid-based nanoconjugate of TMZ is a compound of the formula:
or a derivative thereof, wherein the derivative is an imidazotetrazine compound having antitumor activity;
and
a pharmaceutically acceptable carrier.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

13/513,145Filed 10 Dec 2010 · us provisional application

Priority

10 Dec 2009

Published

US 2012/0328555 A127 Dec 2012

Granted

22 Jul 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification26 codes

A61K 47/65
The modifying agent being a protein, peptide or polyamino acid: peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 31/4188
1,3-Diazoles: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/425
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: thiazoles
A61K 31/495
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with two or more nitrogen atoms as the only ring…

Drug delivery of temozolomide for systemic based treatment of cancer

Life of this patent

Drug delivery of temozolomide for systemic based treatment of cancer

Life of this patent

Abstract

Claims2